4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Lease Termination Agreement with GNS South Tower, LP Executed
Material Contracts, Reg. FD
Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets
Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Implements Workforce Reduction of 70%
Kezar Life Sciences Repays $6.3 Million Under Loan Agreement
Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Reports Second Quarter 2025 Financial Results and Provides Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration of Securities
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload